Clinical Trial Detail

NCT ID NCT02317016
Title Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

Rosuvastatin

Age Groups: adult

No variant requirements are available.